

REMARKS

Claims 9-11, 18, 19, 22 and 23 are pending in the present application. Claims 9, 11, 19, and 23 are currently amended. Claims 10, 18, 19, and 22 are withdrawn due to an election.

No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry.

Claim Objection

Claim 9 has been amended to delete "e.g." from the definition of R⁷.

Obviousness-Type Double Patenting

The Examiner rejected claims 9, 11, 19, and 23 under the judicially created doctrine of obviousness-type double-patenting as being unpatentable under over claims 1-8 of U.S. Patent No. 6,900,217.

Without prejudice and solely in the interests of facilitating prosecution, applicants have amended claim 9 to delete the $-NR^1R^2$ from the definition of B and to delete hydrogen from the definition of R¹⁰. In view of the forgoing amendments, applicants respectfully submit that claims 9, 11, 19, and 23 are allowable and respectfully request withdrawal of the rejection for obviousness-type double-patenting.

Rejection under 35 USC § 112, Second Paragraph

The Examiner rejected claims 9, 11, and 19 under 35 USC § 112, second paragraph, for being indefinite. Specifically, the Examiner pointed to the proviso (d) in claim 9, as being unclear how a double bond between E and G could exist.

Without prejudice and solely in the interests of facilitating prosecution, applicants have amended claim 9 to delete the proviso the Examiner rejected. Furthermore, applicants have amended claim 9 to more appropriately describe the elected subject matter.

The Examiner rejected claims 19 because it depends from cancelled claim 1. Accordingly, claim 19 has been amended to be dependant from claim 9 and therefore applicants respectfully request withdrawal of the rejection.

In view of the amendments set forth herein and remarks above, applicants respectfully submit that the pending claims are fully allowable, and solicit the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date:

12/6/05

Respectfully submitted,



Jason G. Tebbutt
Attorney for Applicant(s)
Reg. No. 55,671

Jolene Appleman
Attorney for Applicant(s)
Reg. No. 35,428

Pfizer, Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-4827